Abstract
Levodopa remains the cornerstone for managing Parkinson's disease. Physician's preference usually determines the dopamine agonist chosen for the early phases of treatment. The concept of neuro-protection, however, remains unproven. A better understanding of the cause of the disease and treatment-related complications could make managing Parkinson's disease more rewarding.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Calne D. B., Duvoisin R. C., Koller W. C. Individualizing therapy in patients with disabling Parkinson's disease symptoms. Neurology. 1994 Mar;44(3 Suppl 1):S8–11. [PubMed] [Google Scholar]
- Cedarbaum J. M., Gandy S. E., McDowell F. H. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology. 1991 May;41(5):622–629. doi: 10.1212/wnl.41.5.622. [DOI] [PubMed] [Google Scholar]
- Diamond S. G., Markham C. H., Hoehn M. M., McDowell F. H., Muenter M. D. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol. 1987 Jul;22(1):8–12. doi: 10.1002/ana.410220105. [DOI] [PubMed] [Google Scholar]
- Goetz C. G., Tanner C. M., Klawans H. L., Shannon K. M., Carroll V. S. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet). Neurology. 1987 May;37(5):875–878. doi: 10.1212/wnl.37.5.875. [DOI] [PubMed] [Google Scholar]
- Hughes A. J., Daniel S. E., Blankson S., Lees A. J. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993 Feb;50(2):140–148. doi: 10.1001/archneur.1993.00540020018011. [DOI] [PubMed] [Google Scholar]
- Koller W. C., Pahwa R. Treating motor fluctuations with controlled-release levodopa preparations. Neurology. 1994 Jul;44(7 Suppl 6):S23–S28. [PubMed] [Google Scholar]
- Magni G., Andreoli F., Arduino C., Arsié D., Ceccherelli F., Ambrosio F., Eandi M. [3H]imipramine binding sites are decreased in platelets of chronic pain patients. Clin Neuropharmacol. 1987 Apr;10(2):175–177. doi: 10.1097/00002826-198704000-00008. [DOI] [PubMed] [Google Scholar]
- Rinne U. K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology. 1987 May;37(5):826–828. doi: 10.1212/wnl.37.5.826. [DOI] [PubMed] [Google Scholar]
- Schulzer M., Mak E., Calne D. B. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol. 1992 Dec;32(6):795–798. doi: 10.1002/ana.410320614. [DOI] [PubMed] [Google Scholar]